Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Effect of TET Mutations on DNA Methyltransferase Cytotoxicity and ERV Induction in B and T Cell Malignancies

Juan Carlos Nogues, BS, Zi Michael Wang, BS, Sarah School Chisholm, MA, Mitcell Smith, MD PhD, Eduardo Sotomayor, MD, Katherine Chiappinelli, PhD

Blood (2018) 132 (Supplement 1): 5157.

https://doi.org/10.1182/blood-2018-99-120281

Published: 2018

Journal Articles

Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies

John C. Byrd, MD, Roger Owen, MD, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MBChB, PhD, Bojena Bitman, Nataliya Chernyukhin, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Liat Schwartz-Sagi, MD, Edwin Tucker, MD, Nathan H. Fowler, MD, Matthew J. Streetly, BMBS, PhD MRCP, FRCPath, Adrian Wiestner, MD, Simon Rule, MD, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 4326.

https://doi.org/10.1182/blood.V130.Suppl_1.4326.4326

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Jorge Enrique Romaguera, Hun Ju Lee, MD, Rohinton Tarapore, PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Joshua E. Allen, PhD, Lee Schalop, MD, Andrew Zloza, MD, Chi Young Ok, MD, Maria Badillo, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 5163.

https://doi.org/10.1182/blood.V130.Suppl_1.5163.5163

Published: 2017

Journal Articles

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Tanya Siddiqi, MD, Jeremy S. Abramson, MD MMSc, Daniel Li, PhD, William Brown, MAS, Todd Devries, PhD, Kedar Dave, PhD, Jacob Garcia, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, BS, Andres Forero-Torres, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 193.

https://doi.org/10.1182/blood.V130.Suppl_1.193.193

Published: 2017

Journal Articles

Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma

Yucai Wang, MD, Yanru Wang, MD PhD, Gita Thanarajasingam, MD, Carrie A Thompson, MD, Thomas M Habermann, MD, Grzegorz S Nowakowski, MD, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 2152.

https://doi.org/10.1182/blood.V130.Suppl_1.2152.2152

Published: 2017

Journal Articles

FoxM1: A New Therapeutic Target for Mantle Cell Lymphoma

Hui Guo, MD PhD, Hui Zhang, Makhdum Ahmed, MD MPH, PhD, Yang Liu, MD, Shengjian Huang, PhD, Victoria Zhang, Jeffrey Wang, Elyse Lopez, Elizabeth A Lorence, MPH, Jacqueline Wang, Swathi Balaji, Merolle Maria, Changying Jiang, PhD, Krystle Nomie, PhD, Michael Wang, BS, Liang Zhang, MD PhD

Blood (2017) 130 (Supplement 1): 1469.

https://doi.org/10.1182/blood.V130.Suppl_1.1469.1469

Published: 2017

Journal Articles

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Simon Rule, MD, Martin Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MD PhD, Brad S Kahl, MD, Jose Angel Hernandez-Rivas, Anil Londhe, PhD, Fong Clow, ScD, Sanjay Deshpande, Lori Parisi, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 151.

https://doi.org/10.1182/blood.V130.Suppl_1.151.151

Published: 2017

NARROW

The Effect of TET Mutations on DNA Methyltransferase Cytotoxicity and ERV Induction in B and T Cell Malignancies

Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma

FoxM1: A New Therapeutic Target for Mantle Cell Lymphoma

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only